We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

178 hedge funds and large institutions have $1.96B invested in Rocket Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $3.15M

48% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 50

1.56% less ownership

Funds ownership: 102.06% → 100.51% (-1.6%)

4% less funds holding

Funds holding: 186 → 178 (-8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less capital invested

Capital invested by funds: $2.48B → $1.96B (-$522M)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

Holders
178
Holders Change
-8
Holders Change %
-4.3%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
74
Reduced
50
Closed
27
Calls
$5.17M
Puts
$3.15M
Net Calls
+$2.02M
Net Calls Change
-$15.1M

Top Buyers

1
WP
Woodline Partners
California
+$12.9M
2
EC
EcoR1 Capital
California
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$8M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$7.9M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$34M
2
State Street
State Street
Massachusetts
-$32.5M
3
LGM
Logos Global Management
California
-$21.8M
4
PA
Perceptive Advisors
New York
-$12.7M
5
CAM
Cormorant Asset Management
Massachusetts
-$8.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
A
201
AlphaQuest
New York
– -$166K -6,180 Closed
MLICM
202
Metropolitan Life Insurance Company (MetLife)
New York
– -$94.1K -3,493 Closed
FIM
203
Fernwood Investment Management
Massachusetts
– -$28.5K -1,057 Closed
MPWT
204
MassMutual Private Wealth & Trust
Connecticut
– -$674 -25 Closed
5 6 7 8
9

RCKT Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2024, worth a combined $1.96B — down 21% from $2.48B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RCKT and 21 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 74 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $12.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $34M sold.

  • 178 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2024, down from 186 in Q1 2024.
  • Funds reported $1.96B of Rocket Pharmaceuticals stock for Q2 2024, down 21% quarter-over-quarter.
  • 21 funds opened new Rocket Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
  • The largest Rocket Pharmaceuticals buyer in Q2 2024 was Woodline Partners, an estimated $12.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2024 was Avoro Capital Advisors, an estimated $34M sold.

Based on aggregated 13F filings for Q2 2024.